Twistdx Limited
Registered name: TWISTDX LIMITED
Part of Abbott Laboratories groupTwistdx Limited made £4.4m revenue and £2.3m profit in the year to 31 Dec 2025.
Twistdx Limited’s revenue grew 18% to £4.4m in the year to 31 Dec 2025, with £2.3m profit and 0 employees. The company is classified under “research and experimental development on biotechnology” and is based in Maidenhead; we hold 3 years of its filed accounts.
- Status
- Active
- Location
- Maidenhead, South East
- Age
- 24 yrs · since 2002
- Type
- Private Limited Company
Pass-through vehicle. This looks like a holding, staffing or umbrella company. Its revenue and profit may largely pass through to or from other entities, so the figures may not reflect a standalone operating business. It is excluded from our opportunity lists.
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L |
| Profit & loss | |||
| Revenue (turnover) | £4.4m | £3.7m | £4.4m |
| Cost of sales | −£1.5m | −£1.5m | −£1.9m |
| Gross profit | £2.9m | £2.1m | £2.5m |
| Operating profit | £2.4m | £1.9m | £2.2m |
| Profit before tax | £2.5m | £2m | £2.4m |
| Profit after tax | £1.9m | £1.7m | £2.3m |
| Profit (best available) | £1.9m | £1.7m | £2.3m |
| Employees (average) | 0 | 0 | 0 |
| Ratios | |||
| Profit margin | 42.6% | 47.1% | 52.7% |
| Gross margin | 65.8% | 58.1% | 56.6% |
| Growth (year on year) | |||
| Revenue growth | — | ▼16.1% | ▲18.4% |
| Profit growth | — | ▼7.2% | ▲32.6% |
| Balance sheet — indirect signals, not revenue | |||
| Net assets | — | — | — |
| Source | Accounts · bulk data Sep 2025 | Accounts · bulk data Sep 2025 | Accounts · bulk data Aug 2026 |
How the business works
- Profit margin
- 52.7%
- Profit ÷ revenue.
- Gross margin
- 56.6%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- —
- Revenue ÷ average employees.
- Profit per employee
- —
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now —
- Cash at bank
- —
- Now —
- Headcount
- —
- Now 0
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now —
Group structure
Ownership chain
- Abbott Laboratories (registered outside the UK register)ultimate parent75–100%
- Alere UK Holdings Limited75–100%
- Twistdx Limitedthis company
Bands show the share of ownership each company holds in the one below it.
Sister companies (2)
- Abbott Toxicology LimitedFigures not disclosed
- Unipath LimitedFigures not disclosed
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Takara Bio UK LtdLondon · Research and experimental development on biotechnology
- Revenue
- £3.1m
- Profit
- £97.2k
- Staff
- 9
- Clinuvel (UK) LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £6.4m
- Profit
- £81.6k
- Staff
- 46
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
- Flatiron Health UK LtdST Albans · Research and experimental development on biotechnology
- Revenue
- £9.5m
- Profit
- £239k
- Staff
- 32
- Biopharma Process Systems LimitedWinchester · Research and experimental development on biotechnology
- Revenue
- £10.1m
- Profit
- £142k
- Staff
- 66
- Askbio UK LtdMidlothian · Research and experimental development on biotechnology
- Revenue
- £12.5m
- Profit
- £1.8m
- Staff
- 54
Sources
Latest figures from accounts for the year to 31 Dec 2025 (profit £2.3m), from the Companies House accounts bulk data published Aug 2026. Spotted an error? Request a correction.
Updated from Companies House on 13 Oct 2026
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.